Trevi Therapeutics (TRVI) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Trevi Therapeutics (NASDAQ: TRVI):

• 11/19/2025 – Trevi Therapeutics had its price target raised by analysts at Leerink Partners from $13.00 to $16.00. They now have an “outperform” rating on the stock.
• 11/17/2025 – Trevi Therapeutics was upgraded by analysts at B. Riley to a “strong-buy” rating.
• 11/14/2025 – Trevi Therapeutics had its price target raised by analysts at Morgan Stanley from $18.00 to $19.00. They now have an “overweight” rating on the stock.
• 11/14/2025 – Trevi Therapeutics had its price target raised by analysts at Oppenheimer Holdings, Inc. from $23.00 to $24.00. They now have an “outperform” rating on the stock.
• 11/14/2025 – Trevi Therapeutics had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
• 11/13/2025 – Trevi Therapeutics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $13.00 price target on the stock.
• 10/8/2025 – Trevi Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Trevi Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.